As a companion piece of work, the EWMA POG has worked to provide a series of user-friendly documents to assist those new to (or inexperienced in) research, in starting on the path to plan, conduct, interpret and disseminate findings from an investigation that will improve our understanding of clinical wound healing and raise the evidence level of the work undertaken in this important area. Given the range of wound types that clinicians are involved with, the POG has decided to limit the first of these to venous leg ulcers. In addition, as a European association, the focus will be on EU regulations and directives.
The target audience for this publication is hospital It would be very tempting to include all necessary documents in this text, but that would result in a heavy, dense textbook that may put people off doing research. Therefore, our approach will be to signpost relevant existing documents and provide links to websites and documents where regulation specific issues are thoroughly covered. The aim is to produce a user-friendly and practical resource.
Relevant sources of information
1 Gottrup, F., Apelqvist, J., Price, P. Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. J Wound Care 2010; 19: 6, 237-268. 2 NICE Guidelines manual www.nice.org.uk/guidelinesmanual
The format will take the form of short chapters on different aspects of the research process, with many points made in bullet point format. It is not anticipated that researchers will read every page and the associated web links in order, but use it as a pathway through the process, with the text highlighting when it would be useful to take a detour into other resources to get additional information.
In some instances, we will provide you with a mark [!] to highlight points where extra attention is required. The first of these can be found on the right. It is really important that you check the ethical framework and regulations relevant to your country. We have tried to include key points whenever possible but all staff involved in clinical trials will need to be trained on the Good Clinical Practice principles. For example, the practical issues related to managing the ethical issues at a patient and data level can be found in ICH E6 (R1) 6 or the Declaration of Helsinki.
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Relevant EU directives on medical devices and clinical trials can be found at the healthcare-related websites of the European Commission.
8,9
The information is divided into chapters that reflect the different stages of the process; many chapters have multiple subsections so that you can easily find help with a specific issue. We hope that you will find this document useful in putting together your research plans and look forward to reading the papers at some point in the future as you contribute to the evidence base for improved wound healing outcomes.
N.B.: the terms "investigation" and "study" are used interchangeably throughout. "Investigation"
is the common term used for regulatory medical device studies, while "study" is the more general term within academic research.
Relevant links related to ethical issues:
6 ICH E6 (R1) Guideline for Good Clinical Practice: All studies will need to fall under the ethical guidelines of the grant awarding body -make sure you look at the rules for the award before you start. RCTs must be conducted within the EU Directive on Clinical Trials (Directive 2001/20/EC) and in line with the principles of Good Clinical Practice, which is an international quality standard based on the International Conference on Harmonisation (ICH). 6 All these guidelines are frequently updated; make sure you are using the most current version.
T his chapter includes three main sections that relate to planning your researchbefore you start collecting any data, and includes sections on formulating your research question or hypothesis; choosing the appropriate design; detailed methods to consider and planning how your investigation will be managed.
Research Questions and Hypotheses
Before you even start to think about the details of the 'how' and 'when' to conduct an investigation, you need to be very clear about the rationale for the investigation, and focus on the 'why'. In an investigation that will be used for regulatory purposes (i.e., to obtain data to acquire a licence for a new product), all such education/training will need to be recorded and documented.
If you are in a position to observe a whole cohort of patients in a structured way over a defined period of time (cohort study), you may be able to observe patterns in the data around the relationship between type of intervention and
For an overview of typical study types, please see: In addition to the overall study design, it is important to define:
• The conceptual framework of the investigation - do you wish to demonstrate superiority/noninferiority/equivalence of a treatment strategy or product?
• The allocation ratio of patients to the groups you are comparing.
Methods: Participants
The key issue is to select the appropriate patients For every study, you must define:
1. Eligibility criteria:
• Inclusion criteria: Who will be eligible to take part?
• Exclusion criteria: Who will be excluded from the investigation?
• Criteria and procedures for subject withdrawal or discontinuation.
Setting and locations for data collection
Where will the investigation take place (e.g. community or hospital?)
Number of patients and timelines
• The point of enrolment: when will they start in the investigation?
Specific for RCTs
The key distinguishing feature of the RCT is that study subjects, after assessment of eligibility and recruitment, are randomly allocated to receive one or other of the alternative treatments under investigation.
Specific for cohort studies
A cohort study is a form of longitudinal study (a type of observational study). A cohort is a group of people who share a common characteristic or experience within a defined period, e.g., are exposed to a drug or undergo a certain medical procedure. The comparison group may be the general population from which the cohort is drawn, or it may be another cohort of persons thought to have had little or no exposure to the procedures under investigation.
Frequent mistakes:
• Small samples sizes/groups investigated are combined with multiple outcome measures, resulting in weak data.
• Randomisation method(s) are poorly, or not, described.
For more information about selection of subjects, please see:
• Expected duration of each subject's participation (time for participation in investigation)?
• Expected duration of the investigation
• Estimated time needed to select the required number of patients (i.e. enrolment period).
Each investigation site should maintain a log of all the subjects enrolled in the clinical investigation, assigning an identification code linked to their names, alternative subject identification or contact information.
Methods: Interventions
The interventions for each group must be described in sufficient detail to allow for replication of the investigation.
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The description of the interventions should include:
• Rationale behind intervention
• Details of the intervention
• The prognostic factors for the treatments groups Control/comparator interventions:
• Rationale for the control or comparator in the
Specific for RCTs
To access sufficiently large numbers of patients to make the data meaningful, multicentre trials are recommended. Efforts should be made to enrol sufficient numbers at each site used in the investigation in order to evaluate potential differences in outcomes across sites.
Specific for cohort studies
Although cohort studies allow you to follow a large group of patients, it is really important to ensure that you are collecting standardised data on each patient so that good comparisons can be made between those that receive different interventions.
Frequent mistakes:
• Power size: Studies often do not show statistical differences because the sample size is too small. Make sure you work with a statistician at the planning stage to work out how many patients you will need • Patient characteristics are not predefined: this makes the interpretation of the data very difficult (you could make a type 1 or type 2 error; see section 2.2.5 on sample sizes for further information about error types).
For more information about the clinical investigation plan and selection of subjects, please see: 15 ISO 14155: 2011 (Annex A) For more information about the various endpoints relevant for chronic wounds in general, please see:
1 Gottrup, F., Apelqvist, J., Price, P. Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. J Wound Care 2010; 19: 6, 237-268.
For a detailed list on relevant endpoints and measurement methodologies in compression device studies, please see: 
Methods: Outcome measures
Clearly defined primary and secondary outcome measure(s) and, when applicable, any methods used to enhance the quality of measurements (e.g. table 1 for further information about methods related to these endpoints). 17 However, some of these outcome may be difficult to achieve.
Specific for cohort studies
If the cohort studies take place over a long period of time it is important to ensure that the setting and context of the intervention does not change significantly and that instructions are given to newly involved clinicians.
Frequent mistakes:
• Lack of comparable baselines for patient groups. E.g. standard care is not sufficiently described.
Specific for RCTs
Given the need for multicentre trials to recruit large samples, the training of assessors is important to ensure that everyone uses the same robust and reproducible measurement technique. Use blinded assessment wherever possible (See chapter 2.2.7 on blinding).
Specific for cohort studies
Often, cohort studies take place over a long period of time. In this case it is important that new staff who work at the centre are trained to ensure that predefined data are captured consistently over time.
Frequent mistakes:
• The primary outcome measure selected is not appropriate for the intended purpose of the intervention.
• The outcome measure is not predefined or is insufficiently defined.
• The outcome measures are not measured by a blinded assessor.
• Photos are not comparable or are not analysed correctly.
Methods: Sample size
The sample size for a trial needs a good balance between medical and statistical considerations.
Ideally, an investigation should be large enough to have a high probability (power) to detect a clinically important difference of a given size.
Large samples are necessary to detect small differences.
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Elements of the sample size calculation include:
• the estimated outcomes in each group (which implies the clinically important target difference between the intervention groups);
• the type I (α) error level ( i.e., false positive error; see Appendix 4);
• the statistical power or the type II (β) error level (i.e., false negative error; see Appendix 4);
• for continuous outcomes, the standard deviation of the measurements.
However, many areas of investigation, such as wound healing, do not have sufficient preliminary data on which to base these calculations.
1 Therefore, it is essential to obtain routine clinical data on the impact of care before initiating an investigation.
Within wound management studies, you may need to consider using a stratified sampling method.
This method of sampling produces characteristics in the sample that are proportional to the overall population of patients with a given wound type, particularly where this is known to influence healing (for example, the size of the wound).
It is important to indicate how the sample size was determined. A formal power calculation should be used whenever possible; the authors Recanalisation of a vein Lipodermatosclerotic skin changes incidence of complete healing, area-planimetry, area in cm Ulcer healing symptoms on analogue scale including pain, CEAP, classification and VSS, QoL
should identify the primary outcome on which the calculation was based, the values used in the calculation, and the resulting target sample size per study group.
Details should be given of any allowance made for attrition or non-compliance during the investigation and expected drop out rates should be defined. In addition, criteria for ending the clinical investigation on statistical or ethical grounds should be defined. To ensure that this is done correctly, please make use of specialist statistical advice.
Methods: Randomisation
The key distinguishing feature of an RCT is that study subjects, after assessment of eligibility and recruitment, but before the intervention to be studied begins, are randomly allocated to receive one or other of the alternative treatments under investigation. This is the central principle for high quality evidence required to demonstrate a possible causal relationship.
18
With random allocation, each participant has a known probability of receiving each intervention before one is assigned, but the assigned intervention is determined by a chance process
and cannot be predicted.
In designing your investigation, you will need a randomisation procedure to generate an unpredictable sequence of allocations, such as a simple random assignment of patients to any of the groups at equal probabilities. You will also need to think about allocation concealment, which refers to the strict precautions taken to ensure that the assignment of patients to a particular group/ intervention are not revealed prior to definitively allocating them to their respective group.
Authors should provide sufficient information so that the reader can assess the methods used to generate the random allocation sequence and the likelihood of bias assigning a patient to a particular group. This should include a description of:
• The method used to generate the random allocation sequence, including details of any restrictions (e.g. blocking, stratification)
• The method used to implement the random allocation sequence, clarifying whether the sequence was concealed until the interventions were assigned (to avoid bias).
For more information about sample size definition, please see: 
Specific for RCTs
Recruiting a sufficiently large sample size is often a significant problem in the wound healing studies as most wounds are not directly comparable and the majority of patients are old and fragile, and suffer from diseases which may influence wound healing rates
Specific for cohort studies
Cohort studies may be considered a preferable study type within the wound area due to the problem with achieving a sufficient sample size.
Frequent mistakes:
• The intended sample size is not described in sufficient detail in the methods section of the trial publication.
• The trial is under-powered (i.e., an insufficient sample size was recruited to achieve statistically significant results).
• Who generated the allocation sequence, who enrolled the participants, and who assigned participants to their group?
There are no specific issues for trials in wound care that are different to studies in other health conditions and essential details should be reported.
Although there is still debate on the appropriate variables that should be used for stratification, most commonly they are ulcer size and duration.
Given the need for an increased use of multicenter trials, the question of stratification by centre should be considered.
Important terminology:
• Simple randomisation: Pure randomisation based on a single allocation ratio.
• Restricted randomisation: Any randomisation not defined as simple (e.g. blocked)
• Blocked randomisation: Used to ensure balance of the numbers in each group
• Stratified randomisation: Used to ensure good balance of participant characteristics in each group.
• Minimisation: Ensures balance between intervention groups for several patient factors (e.g. age)
Methods: Blinding (masking)
Blinding is a procedure that prevents study participants, their caregivers, or outcome assessors from knowing which intervention was received.
Blinding is important because participants, healthcare providers, data collectors as well as data analysts can potentially introduce bias into a trial through knowledge of the treatment assignments. Frequent mistakes:
• "Random" is often used inappropriately in the literature to describe trials in which non-random, deterministic allocation methods were used, such as alternation, hospital numbers, or date of birth. When investigators use such non-random methods, these must be described precisely.
• It is important that information on the process of randomisation is included in the body of the main article and not as a separate supplementary file, where it can be missed by the reader.
Specific for RCTs
Main steps in a typical randomisation process: 3
• Sequence generation: Generate allocation sequence using a random procedure • Allocation concealment: Develop allocation concealment mechanism (such as numbered, identical bottles or sequentially numbered, sealed envelopes) and prepare the allocation concealment mechanism using the allocation sequence from the sequence generation step.
• Implementation: Enrol participants (assess eligibility, discuss the trial, obtain informed consent, enrol participants in the trial), ascertain intervention assignment (e.g., opening next envelope or use a central computerised service) and administer intervention. 
Methods: Statistical methods
It is essential to specify which statistical procedure will be used to compare groups for the primary outcome. For specific considerations on wound care and blinding, please see:
Specific for RCTs
Often, terms such as single or double blind are used. This should be avoided wherever possible as there is great variability in the clinician interpretation and textbook definitions of these terms.
Suggestion for handling blinding within wound care studies:
If possible, make sure dressings have a similar appearance and let one assessor provide the care, while another person assesses the wound and a third person assesses the photo planimetry.
Frequent mistakes:
• No reports on whether and how blinding was used • Blinding is not used for all relevant groups and there are no descriptions of how this may influence the results (risk of bias).
• If full blinding is not possible, the minimum requirement is a blinded assessment technique or an independent evaluation. It is really important to make sure you get appropriate help and guidance from a statistician at the planning stage, and not once the data has already been collected. 
Organisation and management

Specific for RCTs and clinical cohort studies
Intention-to-treat analysis refers to preserving the full benefit of the randomisation by including all randomised participants according to their group allocation. However, this is often difficult to achieve due to missing outcomes from some participants and non-adherence to the original protocol (e.g., when some participants did not meet the inclusion criteria or received a proscribed intervention).
A "per-protocol analysis" may be used in conjunction with the intention-to-treat analysis. The per-protocol analysis is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
• Statistical procedures used are not thoroughly described.
• Multiple observations from one participant are treated as independent data. This is a serious error.
• Post-hoc subgroup analysis (performed after looking at the data) is used. This has a low credibility and should be avoided.
• Avoid common ways to boost samples, e.g.:
• Different wounds on the same patients are placed in different groups • Two centres are involved, but 90% come from one of the centres (balance required).
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well as the study procedures and responsibilities of all involved persons. This will depend on the type of investigation, but all study designs require, as a minimum, a protocol defining exact timing and responsibilities for all actions needed to perform the investigation.
Important documents to ensure proper study management
The • Patient information sheet and consent form: 15, 19 Used to inform and obtain consent from patients concerning the use of their anonymised data; patients must be fully informed about the details of the investigation as well as the potential benefits and risks associated with participation.
Patients must be made aware that they can withdraw from the study at any time without any explanation or detriment to their ongoing clinical care.
• Severe adverse event reporting form (SAE):
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For medical device trials you should take a look at methods to classify adverse events related to devic-es in particular.
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These may be classified as 'non medical complaint', adverse event (AE), serious adverse event (SAE), adverse device effect (ADE), serious adverse device effect (SADE), or unanticipated serious adverse device effect (USADE).
• Study contracts with the centres and all relevant staff.
For responsibilities of the study investigators and planning document examples, please see:
ISO 14155:2011(E)
For detailed information about patient information sheet and the Informed Consent Form (ICF), please see: 
Centres & study personnel -qualifications
The study sponsor is responsible for defining The lead investigator in each centre/site is responsible for demonstrating that the centre has the required number of eligible subjects needed for the investigation and that the centre has the adequate facilities and a qualified investigation team to run the study. All roles and responsibilities must be described and formally agreed in writing.
The sponsor is also responsible for recording the level of knowledge and experience of centres and investigators involved in the study, and for providing training if necessary/required.
A possible layout for recording all relevant employees at a study centre can be found in Appendix 2.
Contract research organisation (CRO)
The CRO may be a person or organisation contracted by the sponsor to perform one or more of the sponsor's clinical investigation-related duties and functions. These functions should be summarised in a contract.
Patients/participants enrolment
Important documents related to the subjects/ participants in the study are:
• A recruitment status sheet/subject identification log which presents an overview of and status on the subjects registered for the investigation.
An identification code should be assigned to all subjects.
• An informed consent form, approved by the relevant ethical panel/committee: all subjects who agree to participate in the investigation must sign this prior to any involvement
For more information about the responsibilities of the principal investigator appointed in the involved centres, please see:
(See chapter on risk management for further information).
• Case Report Form (CRF): this document must capture all the relevant data for each enrolled subject. All subject data must be kept strictly confidential and in line with the country-specific data protection legislation.
• An example of a combined recruitment/ monitoring form can be found in appendix 3.
Clear inclusion and exclusion criteria must be defined for recruitment purposes. You can find a set of criteria examples in Table 2 .
An estimation of expected withdrawal rate/drop out rate should be performed prior to the initiation of the study (e.g. based on results from other published clinical investigations on comparable therapies). You can find an example of possible withdrawal criteria in Table 3 .
Table2:Sideeffects-Generalinclusionandexclusioncriteria
Criteria Ulcus cruris venosum 
Financial plan
For more information about sponsor role and financing, please see: 
Specific for RCTs
Detailed instructions for the RCT must be written in the protocol and followed rigorously. The decisions of the Ethical Committee (pre-and post-market), and approvals from the responsible authorities should be included in the study file (especially for pre-market product trials).
Specific for cohort studies
• Study details must be written in the protocol and followed rigorously.
• The clinical data may be evaluated retrospectively or prospectively.
• The medical devices must be used according to their "instructions for use" (post-market study).
The sponsor needs to ensure that a financial plan is developed for the clinical investigation.
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The financial budget must guarantee that the clinical investigation can be performed and include a plan for loss of the study sponsors (e.g. due to insolvency) or early termination of the clinical investigation. Usually the financial budget will be evaluated by the Ethical Committee, as well as the responsible authority.
Frequent mistakes:
• A list of frequent mistakes related to study management is provided in Table 4 •No contracts are prepared.
•The different tasks of various participants are not described (e.g. sponsor, principal investigator, clinical investigator, supporting clinical staff in the center)
•No financial plan is prepared.
•Study forms are incomplete.
•Informed consent form for patients is not clear.
•Missing ethical approval or approval by authorities.
•Parts of the investigators brochure are missing (e.g. biocompatibility, assessment of the benefit-risk of the clinical investigation).
•Statistical evaluation is not fit for purpose (e.g. low study power, references analysis patterns in other studies are missing).
•Monitoring/auditing is not sufficient (e.g. too many open queries, no correct adaptions in the CRFs by investigators, informed consent form is not signed by the patient or the patient was not properly informed by a physician).
•Reporting of (serious) adverse events is insufficient (no timely reports from clinical investigators/sponsors, bad coordination, no presentation of corrective actions when needed).
•Clinical investigators have no experience with medical device studies and the related regulations.
•Incorrect selection of the comparison group (definition of standard care missing).
•Recruitment of patients in each centre is insufficient within the defined time frame.
•No validation of subjective assessment.
•No description of objective or subjective measurement techniques.
•No comparable baseline for patient groups.
•No blinding in the evaluation of primary outcomes.
•Incorrect randomisation methods.
•Poor definition of primary and secondary objectives/outcome measures
•Patient numbers are not based on a prior sample size calculation.
•Randomisation method poorly/not described.
•Assessment of outcome measures not fully objective.
•'Intention-to-treat' analysis is not used.
•Heterogeneous study populations.
•Number of and reasons for dropouts are not stated.
•No specification of adjuvant treatments.
•Small sample size combined with multiple outcome measures.
•Reporting of multiple outcomes over several time periods (increases occurrence of type 1 errors). It is good practice to appoint a committee of independent clinical and statistical experts to review study data on one or more planned occasions while the investigation is ongoing.
After each data review meeting, the monitoring committees will make recommendations to the sponsor or investigation steering group, that are also reported to institutional review/ethics boards.
For example, the data monitoring committee can recommend protocol amendments, additional study procedures to assess safety or efficacy, or early termination of an investigation for reasons of safety or efficacy.
Data collection must reflect the study protocol content and be unambiguous in the sense that they provide the information needed to answer the questions defined in the protocol (See chapter 2.2 methods).
The overall responsibility for the quality assurance of the study lies with the study sponsor.
For quality assurance measures and quality control in the data collection the following actions must be taken:
• Maintain written quality procedures to ensure that data are generated, documented and recorded in compliance with international standards (e.g., ISO 1415515).
• Maintain records to document the compliance of all parties involved in the investigation (see chapter 2.3.1).
Accepted Practice Application to Wound Management
Selection bias (All eligible patients should have the same chance of receiving the intervention. Both groups are similar at baseline) Random allocation, concealed allocation
There are no particular issues for wound management studies, and all efforts should be made to randomly allocate patients to groups.
Performance bias (All patients should receive exactly the same treatment with the exception of the study intervention)
Participants are blinded to treatment allocation. Clinicians (who administer an intervention) are blinded to treatment allocation
The details of standard treatments should be made explicit. It may be difficult to achieve, but the highest level of blinding should be used within an RCT. Double blind studies are often difficult but blinded (or independent) assessment of outcome/ endpoint should be mandatory (especially if the study is not blinded). Blinded analysis of data should be easy to undertake..
Table5:Selectionbiasandperformancebias
Minimum dataset
In order to increase the potential for studies to be compared robustly, or be collated into a metaanalysis, it is important that we start to develop Currently, there is no standard use of minimum dataset within wound management research.
EWMA considers this is an important next step to secure more comparable data in wound research.
This would also meet the requests for more cross
European data on best practice treatment methods and health economical aspects.
The suggested dataset listed in table 6 includes our proposals for the information you need to provide about the patient to give the basis for your evaluation of the outcome of the product or treatment method in question.
These are based on an evaluation of the key issues that we know affect the outcome of venous leg ulcers and should be taken into consideration when defining the outcome measures of the study. These could be factors influencing the generalisability of the data.
For general information regarding minimum dataset, see for example: In order to avoid bias, it is a good idea to separate data collection and the study conduct from the data analysis and reporting (i.e., these are undertaken by different staff).
In the following section, you will find some general and wound related advice on data management, analysis, interpretation, reporting and publication.
Please note that different rules apply to reporting to ethical committees in different countries. 
Data management
The following aspects of good data management are crucial for good study conduct and should always be followed to ensure that study quality and ethical standards are met.
Data documentation
All subjects enrolled in the clinical investigation (including those withdrawn or lost to follow up)
should be accounted for and documented in order to prove that data was not invented and to avoid double entries. This is typically done by securing that patient data are signed and dated and may be handled by using a recruitment/monitoring form (see Appendix 3), or electronic database. If such a withdrawal is due to problems related to the investigational device safety or performance, the investigator should ask for the subject's permission to follow his/her status/condition outside the clinical investigation.
To avoid attrition bias, the general/recommended
practice is to ensure that:
• All groups are followed-up at the same time;
• Rates of drop-out are not high in either group;
• Both groups should be similar in terms of patients remaining in the analysis (and similar to baseline).
Confidentiality
Everyone involved in the investigation, and at all times throughout the clinical investigation, must observe all requirements related to the confidentiality of patient data and study outcomes.
All data must be secured against unauthorised access. The privacy of each subject and confidentiality of his/her information shall be preserved in reports and when publishing any data.
Access to data
The principal investigator or institution shall provide direct access to source data during and after the clinical investigation for monitoring, audits, Ethical Committee (EC) review and regulatory authority inspections. It is also required that the principal investigator or institution obtains permission for direct access to source documents from the subject (informed consent is presupposed; see chapter 2.3.5), hospital administration and national regulatory authorities before starting the clinical investigation.
Analysis
Analyses, e.g. performance of a medical device such as a wound dressing, that were pre-specified in the trial protocol (prepared in the initial phase)
should be used. If subgroup analyses were not pre defined, authors should report which subgroups were examined and include justification for these analyses.
You should therefore report which analyses were pre-specified and make the trial protocol available so that interested readers may access this to find information.
For company-sponsored research or if you wish to publish the results of your research in highly recognised journals, it is mandatory that the study is registered in a public database (e.g. www.
clinicaltrials.gov 25 ) before the investigation begins.
You should therefore consider this requirement in advance.
In general, it is recommended that the following information is included in the analysis:
1,3,13,15
• Performance and safety assessment:
• Identify datasets that are considered most important in contributing to the demonstration of the overall performance.
• Provide a summary of all adverse events and adverse device events, including a discussion of the severity, treatment needed, resolution and relevant principal investigator's judgment concerning the causal relationship with the investigational devices or procedure;
• Provide a table compiling all observed device deficiencies that could have led to a serious adverse device effect, and any possible corrective actions taken during the clinical investigation.
• Pre-planned subgroup analyses for special populations (i.e. gender, racial/cultural/ethnic 25 www.clinicaltrials.govis an official platform and catalogue for registering a clinical trail. ClinicalTrials.gov, run by the United States National Library of Medicine (NLM), was the first online registry for clinical trials and is the largest and most widely used internationally today.
subgroups), as appropriate;
• An account of all subjects with a description of how missing data or deviation(s) were dealt with in the analysis, including subjects not passing screening tests, lost to follow-up, withdrawn or discon-tinued from the clinical investigation and the associated reasons (see data management).
Interpretation
The interpretation of data should identify meaningful clinical observations and report the clinical meaning and relevance of outcomes. As a result of good initial planning and the appropriate definition of the primary outcome measures, the results should be interpretable within the size of the sample selected for inclusion in the study.
To avoid detection bias, the interpretation must be based on the initial planning of the investigation as outlined in the box.
As previously mentioned, blinding may be a challenge in wound studies, but this recommendation should be met whenever possible (See in chapter 2.2.7 methods: blinding).
In order to make generalisations about the findings, issues with regards to external validity and applicability of the findings should be considered. These considerations should be made in the planning phase, as the data collection must support these aspects of the interpretation (e.g., the risk of a healthy selection bias may compromise the validity of generalised results). To avoid detection bias:
• Provide a precise definition of outcome including adequate follow-up periods allowing for recurrence rates; • Define a valid and reliable method to measure outcome (the outcome measure should be objectively measurable and repeatable); • Ensure an appropriate length of follow up which is adequate to identify outcomes; • Make sure investigators (responsible for assessing outcomes) are blinded to initial treatment allocation; • Make sure investigators are blinded to other important confounding or prognostic factors
Limitations:
• Remember to discuss the relevant limitations of the study that were not anticipated as part of the interpretation of data. A discussion about the reason(s) for unforeseen limitations and what they may tell us about the outcome measures in question may be a relevant and a useful part of the interpretation of findings, which should not be ignored.
For more information about analysis of data and reporting, please see: 
General details
• State all relevant details on name of product or treatment method.
• For products, include manufacturer details.
• Include name of the principal investigator/ coordinating investigator.
• State whether the investigation was conducted in accordance with international standards and applicable regulations.
Summary
Brief summary of the key report content, according to the purpose of the study. • Intended therapeutic and/or diagnostic indications and claims
• Describe essential requirements relevant to the product or treatment method (e.g. performance or safety).
Clinical investigation
• Context of the evaluation, outcome measures and choice of clinical data types.
• Ethical considerations and data quality assurance • Data analysis
• Performance: Provide a description of the analysis used to assess performance.
• Safety:
• Describe the total experience with the product or treatment method (including numbers and characteristics of patients exposed to the device; and duration of follow-up)
• Give a summary of related adverse events, paying particular attention to serious adverse events.
• State whether end user training is necessary.
• 
Conclusions
• Outline clearly the conclusions reached about the safety and performance of the product or treatment method from the evaluation, with respect to the intended use.
• State whether the risks identified have been addressed by the clinical data. 
Scientific articles
As a minimum, the study report and papers submitted for publication should include the following sections:
• Abstract: Background for the investigation, why ask this research question?
• Methods: What did I do?
• Results: What did I find?
• Discussion: What might it mean? For example,
• Considerations of possible mechanisms and explanations, including safety and performance results and assessment of risks and benefits.
• Comparison with relevant findings from other published studies
• Limitations of the present investigation (and methods used to minimise and compensate for those limitations).
• A brief section summarising the clinical and research implications of the work, as appropriate for the investigation in question.
You may also add a conclusion stating whether the study objectives were achieved and key messages from the study, depending on the style requirements of the journal. 
